Brian Scorny
Analyst
Baird
Equibles does not estimate personal net worth.
About Brian Scorny
Brian Scorny is recorded as Analyst at Baird. Brian Scorny has spoken on 4 earnings calls and 1 other investor event across 5 companies, most recently for Lexeo Therapeutics, Inc. on September 15, 2026. Those appearances were for Lexeo Therapeutics, Inc. (LXEO), Neurocrine Biosciences Inc (NBIX), Crinetics Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. (MIRM) and Sarepta Therapeutics, Inc. (SRPT). The companies whose calls Brian Scorny spoke on are classified in the Healthcare sector.
Brian Scorny on recent calls
“I'm one of Baird's senior biotech analysts. I'm really thrilled to have a fireside chat with management of Lexio Therapeutics. This is a company that I've been following for a couple of years now.”
“I may need to jump in with a question on VyCat as well. You know, I think during the Selena days, there's a lot of debate on sort of the differences between sort of new start boluses and sort of dropouts.”
“Also wanted to get some thoughts maybe on the XUS launch you mentioned sort of thinking about prioritizing where reimbursement may be favorable given sort of the IRA dynamics.”
“I guess I'd love to also ask a question on FOP, too. It seems like you're doubling down on making it your corporate nemesis.”
“I guess, you know, the study's been running for 10 years now, and the original design was six-minute walk, and I don't think it was changed to this four-step ascend velocity until under a year ago, and prior to that, it wasn't flagged as, like, a secondary endpoint.”
Affiliation history
-
Baird
Analyst
Transcript header (unverified)
Current
Company network
Drug Manufacturers - Specialty & Generic · Healthcare
Crinetics Pharmaceuticals, Inc.
Biotechnology · Healthcare
Recent activity
-
-
-
Earnings call
Crinetics Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Crinetics Pharmaceuticals, Inc.
-
-